Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 2/20 | 0.35 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.35 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.35 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.35 |
| ▸ | PDE3B | Q13370 | 2/20 | 0.35 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.35 |
| ▸ | PGR | P06401 | 5/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20267946 | 0.81 | PGR (0.35) | PDE4APDE4BPDE4CPDE4DPDE3B | |
| SCHEMBL16849905 | 0.77 | PDE7A (0.35) | PDE4APDE4BPDE4CPDE4DPDE3B | |
| SCHEMBL31430376 | 0.73 | PDE7A (0.37) | PDE4APDE4BPDE4CPDE4DPDE3A | |
| SCHEMBL4813479 | 0.73 | PGR (0.41) | PGRALDH1A1LMNATP53HTT | |
| SCHEMBL16849927 | 0.71 | KMT2A (0.39) | PDE4APDE4BPDE4CPDE4DPDE3B | |
| SCHEMBL5499005 | 0.70 | PGR (0.55) | PDE4APDE4BPDE4CPDE4DPDE3B | |
| SCHEMBL16849925 | 0.69 | PDK2 (0.36) | PDE4APDE4BPDE4CPDE4DPDE3B | |
| SCHEMBL31492415 | 0.68 | PGR (0.33) | PDE4APDE4BPDE4CPDE4DPDE3B | |
| SCHEMBL16849901 | 0.68 | PDK2 (0.39) | PDE4APDE4BPDE4CPDE4DPDE3B | |
| SCHEMBL16849903 | 0.68 | CAMK1D (0.40) | PDE4APDE4BPDE4CPDE4DPDE3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10336697-B2 | Spiro[cyclobutane-1,3′-indolin]-2′-one derivatives as bromodomain inhibitors | ORION CORPORATION (FI) | 2019-07-02 | — | — | US | disclosed |
| US-20180186739-A1 | SPIRO[CYCLOBUTANE-1,3'-INDOLIN]-2'-ONE DERIVATIVES AS BROMODOMAIN INHIBITORS | ORION CORPORATION (FI) | 2018-07-05 | — | — | US | disclosed |
| WO-2018109271-A1 | NEW BROMODOMAIN INHIBITORS | ORION CORPORATION (FI) | 2018-06-21 | — | — | WO | disclosed |
| EP-3310772-A1 | SPIRO[CYCLOBUTANE-1,3'-INDOLIN]-2'-ONE DERIVATIVES AS BROMODOMAIN INHIBITORS | Orion Corporation (FI) | 2018-04-25 | — | — | EP | disclosed |
| WO-2016203112-A1 | SPIRO[CYCLOBUTANE-1,3'-INDOLIN]-2'-ONE DERIVATIVES AS BROMODOMAIN INHIBITORS | ORION CORPORATION (FI) | 2016-12-22 | — | — | WO | disclosed |
| WO-2016203112-A1 | SPIRO[CYCLOBUTANE-1,3'-INDOLIN]-2'-ONE DERIVATIVES AS BROMODOMAIN INHIBITORS | ORION CORPORATION (FI) | 2016-12-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10336697-B2 | Spiro[cyclobutane-1,3′-indolin]-2′-one derivatives as bromodomain inhibitors | BRD4, BRD3, BRD1 | PDE4A 1276/4885PDE4B 1550/4885PDE4C 2178/4885 |
| US-20180186739-A1 | SPIRO[CYCLOBUTANE-1,3'-INDOLIN]-2'-ONE DERIVATIVES AS BROMODOMAIN INHIBITORS | BRD4, BRD3, BRD1 | PDE4A 1285/4885PDE4B 1548/4885PDE4C 2172/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.